Under the terms of the new agreement, Balchem will provide its Pharmashure taste-masking technology for Auriga to utilize in its prescription pain products. This micro-encapsulation technology provides a barrier to the sharp taste and acridness often associated with orally administered rapid-dissolve drugs.
Auriga hopes that this strategic initiative will allow the company to capitalize on high-revenue opportunities in the multi-billion dollar pain and respiratory marketplaces. Two product candidates have already been identified for development.
“We believe Balchem’s superior encapsulation technology will have substantial market advantages which will lead to the benefit of improved patient compliance and support the acceleration of our drug product sales and growth,” commented Philip Pesin, CEO of Auriga.